Experimental Nogo Antibody Therapy Enables Swiss Tetraplegic to Walk Again
Peter Thomann, 75, regained the ability to walk after receiving an experimental Nogo-blocking antibody in a Swiss clinical study.
After a severe bicycle accident left Peter Thomann with an incomplete tetraplegia at the C5/C6 level, he enrolled in a trial at Balgrist Hospital. The trial tested an antibody that inhibits the Nogo protein, which normally prevents nerve regrowth after injury. Thomann’s condition improved enough for him to stand and walk again, marking a notable success among the fourteen participants studied.
Why it matters
It shows a promising new approach to restore movement in people with severe spinal-cord injuries.
In this story
Nogo antibodytetraplegiaspinal cord injuryclinical trialnerve regenerationBalgristexperimental therapyrehabilitation
